SeaCrest Wealth Management’s Summit Therapeutics SMMT Stock Holding History

SeaCrest Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-22,717	Closed	-$483K	–	670
2025 Q2	$483K	Sell	22,717 -2,203	-9%	-$50.2K	0.05%	322
2025 Q1	$481K	Buy	24,920 +41	+0.2%	+$823	0.05%	342
2024 Q4	$444K	Buy	+24,879	New	+$482K	0.05%	373
2019 Q2	–	Sell	-22,322	Closed	-$41K	–	1641
2019 Q1	$41K	Buy	22,322 +21,597	+2,979%	+$35.4K	0.01%	1014
2018 Q4	$1K	Hold	725	–	–	﹤0.01%	2064
2018 Q3	$2K	Buy	725 +403	+125%	+$928	﹤0.01%	2086
2018 Q2	$1K	Buy	322 +160	+99%	+$2.05K	﹤0.01%	2137
2018 Q1	$2K	Buy	+162	New	+$2.02K	﹤0.01%	2006

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACL

APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

SeaCrest Wealth Management's SMMT Position: Q3 2025 in Review

SeaCrest Wealth Management sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 22,717 shares — an estimated $483K sold.

SeaCrest Wealth Management first reported a position in SMMT in Q1 2018 and held it in 8 quarters. The position peaked at $483K in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

SeaCrest Wealth Management reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
SeaCrest Wealth Management sold 22,717 Summit Therapeutics shares in Q3 2025, an estimated $483K.
SeaCrest Wealth Management first reported a position in Summit Therapeutics in Q1 2018 and held it in 8 quarters.
SeaCrest Wealth Management's Summit Therapeutics position peaked at $483K in Q2 2025.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on SeaCrest Wealth Management's 13F filing for Q3 2025, filed 13 Nov 2025.